Condition: Diabetic Foot Ulcer · Sponsor: Anterogen Co., Ltd.
This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months
This description comes directly from the study's public registry record.
ChangSik Park, MD. Ph D · +82 2 3010 3600 · iloveps.jcp@gmail.com
Always discuss trial participation with your own doctor first.
| Soonchunhyang University Hospital | Bucheon-si, Gyeonggi-do, South Korea | Recruiting |
| Bucheon ST. Mary's Hospital | Bucheon-si, Gyeonggi-do, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Borame Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06141811